Intercept Pharmaceuticals Inc

Intercept Pharmaceuticals Inc (ICPT)

-0.56 (-1.41%)
Symbol ICPT
Price 39.09$
Beta 1.611
Volume Avrg. 1.00M
Market Cap 1.29B
Shares (2019) 31,654.00K
Last Div 0
Dividend Yield -
DCF Unlevered -1,403,660.17 Strong Sell
DCF Levered -516,793.77 Strong Sell
ROE -668.56% Strong Sell
ROA -45.66% Strong Sell
Operating Margin -123.98% Strong Sell
Debt / Equity 1364.21% Strong Buy
P/E -8.47 Strong Sell
P/B 56.66 Strong Buy

Retained Earning Schedule

Year 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019
Retained Earnings (Previous Year) --62-75-118-186-469-696-1,108-1,470-1,779
Net Income ---13-68-283-226-413-360-309-345
Stock Dividends -62-13-31-000--1--
Dividend Paid ----------
Retained Earnings -62-75-118-186-469-696-1,108-1,470-1,779-2,123

PPE Schedule

Year 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019
Gross PPE -1002610111610
Annual Depreciation 1-1-03910615-69
Capital Expenditure -0-0-0-2-5-6-5-10-0-1
Net PPE 100261011161018

Intangible and Goodwill Schedule

Year 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019
Intangible and Goodwill (Previous Year) ----------
New Purchases ---65,941-65,941-204,344-641-512-231-436-603
Intangible and Goodwill ----------


Dr. Mark Pruzanski
Nasdaq Global Select

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. The company is headquartered in New York City, New York and currently employs 330 full-time employees. The firm is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The firm's product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions. The firm's product candidate, obeticholic acid (OCA), is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). In addition to OCA, it is developing other bile acid analog compounds targeting FXR and a second dedicated bile acid receptor called TGR5, which is a target of interest for the treatment of type 2 diabetes and other gastrointestinal indications. The firm is also developing other products INT-767 for the treatment of fibrosis and INT-777 for the treatment of type 2 diabetes.